drugset / Trial / NCT02274662

Expanded Access Protocol Thymus Transplantation

NCT02274662

Phase 4 Completed 11 enrolled Sumitomo Pharma Switzerland GmbH
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose is to provide access for patients who have immunodeficiency or severe autoimmune disease related to poor thymic function to cultured thymus tissue for implantation. With no thymus function, bone marrow stem cells do not develop into educated T cells, which fight infection. Eligible participants receive cultured thymus tissue for implantation and may undergo biopsy. Immune suppression may be given depending on the immune status and clinical condition of the participant. Immune function testing is continued for one year post-implantation.

Timeline

Start
2014-08
Primary completion
2023-08
Completion
2023-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Background Cyclosporine Peptide
Background Tacrolimus Small molecule
Background Thymoglobulin Protein / enzyme biologic